EGFR and non-small cell lung carcinoma: Even among NSCLC cell lines harbouring the same driver (EGFR), two different processes have been observed: the acquisition of the drug resistant phenotype by selection of a resistant clone that existed prior to therapy44 and the evolution via de novo changes during therapy45.